Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
174 Leser
Artikel bewerten:
(0)

EQS-News: Edison issues review on BB Biotech (BION)

Dow Jones received a payment from EQS/DGAP to publish this press release.

EQS-News: Edison Investment Research Limited / Key word(s): Capital 
Increase/Investment 
Edison issues review on BB Biotech (BION) 
 
27-Feb-2017 / 15:42 GMT/BST 
 
London, UK, 27 February 2017 
 
Edison issues review on BB Biotech (BION) 
 
BB Biotech (BION) is a long-established investor in biotech innovation, 
offering access to a concentrated portfolio of c 30 companies covering a 
range of therapeutic areas. It seeks to provide long-term capital growth, 
but also offers a yield of c 5% as a result of a capital distribution policy 
adopted in 2012. Performance has been strong both over the long term and 
more recently, with the fund ranking first among peers (in Swiss franc 
terms) over one and five years, and also outperforming the benchmark NASDAQ 
Biotechnology Index over one, three, five and 10 years. Although biotech and 
healthcare stocks may continue to see some near-term share price volatility 
as the direction of US policy becomes clearer, BION's managers point to 
lower-than-average biotech valuations as a source of support. 
 
On 23 February, BION's shares traded at a 2.7% discount to cum-income NAV. 
This is narrower than the 4.2% average discount over the last 12 months, and 
substantially tighter than the longer-term averages, reflecting a 
significant narrowing from late 2015. Factors supporting the narrower 
discount include BION's high distribution policy (yield of c 5%) and share 
buyback programme, as well as consistent performance, a broader shareholder 
base, high levels of daily trading liquidity and inclusion since December 
2014 in the Stoxx Europe 600 Index. 
 
Click here [1] to view the full report. 
 
All reports published by Edison are available to download free of charge 
from its website 
www.edisoninvestmentresearch.com [2]. 
 
*About Edison:* Edison is an investment research and advisory company, with 
offices in North America, Europe, the Middle East and AsiaPac. The heart of 
Edison is our world-renowned equity research platform and deep multi-sector 
expertise. At Edison Investment Research, our research is widely read by 
international investors, advisers and stakeholders. Edison Advisors 
leverages our core research platform to provide differentiated services 
including investor relations and strategic consulting. 
 
Edison is authorised and regulated by the Financial Conduct Authority [3]. 
 
Edison is not an adviser or broker-dealer and does not provide investment 
advice. Edison's reports are not solicitations to buy or sell any 
securities. 
 
*Contact details:*Learn more at www.edisongroup.com [4] and connect with 
Edison on: 
 
+--------+-----------------------------------------------------------+ 
|LinkedIn|https://www.linkedin.com/company/edison-investment-research| 
|        |[5]                                                        | 
+--------+-----------------------------------------------------------+ 
|Twitter |www.twitter.com/Edison_Inv_Res [6]                         | 
+--------+-----------------------------------------------------------+ 
|YouTube |www.youtube.com/edisonitv [7]                              | 
+--------+-----------------------------------------------------------+ 
 
Dissemination of a UK FINANCIAL NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
547933 27-Feb-2017 
 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=b155adea40397b354020acfa542c5478&application_id=547933&site_id=vwd&application_name=news 
2: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e7266211cbf0b72f2b3d94ab8bdaae97&application_id=547933&site_id=vwd&application_name=news 
3: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=105fe9be9b5e36892886e5a39d51d4b7&application_id=547933&site_id=vwd&application_name=news 
4: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=88c95533002fab2316572f9ef6cf3cc6&application_id=547933&site_id=vwd&application_name=news 
5: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=824a704d5aa7fdcb442bc890c7358b08&application_id=547933&site_id=vwd&application_name=news 
6: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ec2d264fe4f303e2143a2e85c6eaa823&application_id=547933&site_id=vwd&application_name=news 
7: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6b959e4d7ee3c402b931a274d2bbe945&application_id=547933&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

February 27, 2017 10:42 ET (15:42 GMT)

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.